Futura Medical plc: Highly positive FM71 Phase 3 study resul

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys drug delivery technology and currently focused on

Related Keywords

United States , Guildford , Surrey , United Kingdom , Georgia , Bulgaria , Poland , London , City Of , Americans , Ken James , Erich Sandoval , Daniel Popoloski , James Barder , Angela Hildreth , London Stock Exchange , Drug Administration , Investor Centre , Efficacy Co , Futura Medical , Chief Executive Officer , Executive Director , African Americans , Action Secondary , Self Esteem , Clinically Important Differences , Erectile Function Domain , International Index , Erectile Function Scale Rosen , Market Abuse Regulation , Market Abuse , London Stock , Chief Executive , Finance Director , Sole Broker , Kane Collings , Futura , Medical , Ighly , Positive , Rm71 , Hase , Study , Results , Primary , Secondary , Endpoints , Chieved , Ed3000 , Remains , Track , Ubmit , Marketing , Authorization ,